Gillian F. Morgan

Most-cited papers

1. Accuracy of the TRUGENE HIV-1 Genotyping Kit

   R. Grant, D. Kuritzkes, V. Johnson, J. Mellors +9 more

   2003Journal of Clinical Microbiology137 citations Open access

   Semantic Scholar

   Save

2. Multicenter, Prospective Clinical Evaluation of Respiratory Samples from Subjects at Risk for Pneumocystis jirovecii Infection by Use of a Commercial Real-Time PCR Assay

   P. Hauser, J. Billé, C. Lass-Flörl, C. Geltner +13 more

   2011Journal of Clinical Microbiology98 citations Open access

   Semantic Scholar

   Save

3. Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System

   D. Kuritzkes, R. Grant, P. Feorino, M. Griswold +7 more

   2003Journal of Clinical Microbiology86 citations Open access

   Semantic Scholar

   Save

4. Evaluation of Analytical and Preliminary Clinical Performance of Myconostica MycAssay Aspergillus When Testing Serum Specimens for Diagnosis of Invasive Aspergillosis

   P. L. White, Michael D. Perry, A. Moody, Sarah A. Follett +2 more

   2011Journal of Clinical Microbiology83 citations Open access

   Semantic Scholar

   Save

5. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

   A. Chari, H. Cho, Amishi Dhadwal, Gillian F. Morgan +15 more

   2017Blood Advances44 citations Open access

   Semantic Scholar

   Save

6. Blood Transfusion Management and Transfusion‐Related Outcomes in Daratumumab‐Treated Patients With Relapsed or Refractory Multiple Myeloma

   A. Chari, S. Arinsburg, S. Jagannath, Toshihisa Satta +8 more

   2018Clinical Lymphoma, Myeloma & Leukemia39 citations Open access

   Semantic Scholar

   Save

7. A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

   A. Chari, H. Cho, Siyang Leng, Amishi Dhadwal +19 more

   201523 citations

   Semantic Scholar

   Save

8. Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab

   A. Chari, Toshihisa Satta, A. Tayal, S. Jagannath +16 more

   20159 citations

   Semantic Scholar

   Save

9. Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma.

   K. Osman, A. Chari, S. Parekh, Christine Pun +10 more

   2016Journal of Clinical Oncology4 citations Open access

   Semantic Scholar

   Save

10. A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

    A. Chari, H. Cho, S. Parekh, K. Lau +14 more

    20164 citations

    Semantic Scholar

    Save

11. Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib

    A. Chari, H. Cho, S. Parekh, K. Osman +13 more

    20153 citations

    Semantic Scholar

    Save

12. Modeling overall survival in the event of patient cross-over from dexamethasone to lenalidomide in phase III multiple myeloma trials

    K. Ishak, B. Deniz, M. Drayson, Gillian F. Morgan +6 more

    20081 citations

    Semantic Scholar

    Save

13. Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

    K. Osman, A. Chari, S. Parekh, Adolfo Aleman +12 more

    20170 citations

    Semantic Scholar

    Save

14. Can we cure Multiple Myeloma by 2020? Yes

    B. Barlogie, F. van Rhee, M. Zangari, Y. Jethava +17 more

    20150 citations

    Semantic Scholar

    Save